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Background: Stroke prevention in elderly patients with atrial fibrillation (AF) can be 
challenging, requiring a balance between thromboembolism prevention and serious bleeding. 
Comparisons of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in the 
elderly, at different age strata (age 65-74, 75-89, ≥90) in the daily practice have not been well 
described, particularly in Asians. We aimed to asses  the clinical outcomes of NOACs 
compared to warfarin for stroke prevention in elderly patients with AF. 
Methods:  From 2012 to 2015, 64,169 AF patients aged ≥ 65 years who received at least 1 
NOAC (dabigatran, rivaroxaban, or apixaban) or warfarin prescription were identified from 
the Taiwan National Health Insurance Research Database. The risks of ischemic stroke, intra-
cranial hemorrhage (ICH), major bleeding, mortality and composite adverse events were 
compared between NOACs and warfarin in all patients age ≥65 and specifically, with 
different age strata; that is 65-74 years, 75-89 years and >90 years.  
Results: Overall NOACs were associated with a significantly lower risk of ischemic stroke 
(adjusted hazard ratio [aHR] 0.869, 95% confidence i t rval [CI] 0.812-0.931), ICH (aHR 
0.524, 95%CI 0.456-0.601), major bleeding (aHR 0.824, 95%CI 0.776-0.875), mortality 
(aHR 0.511, 95%CI 0.491-0.532) and composite adverse vents (aHR 0.646, 95%CI 0.625-
0.667) compared to warfarin. There was heterogeneity in treatment effect for NOACs versus 
warfarin in different age strata, but the results still favored NOACs even among the very 
elderly (> 90 years). The results were generally consistent with propensity matching analysis. 
The absolute risk difference and reductions in ICH and composite adverse events with NOAC 
use were even greater among the elderly compared to warfarin. 
Conclusions: Compared to warfarin, NOACs were associated with a significantly lower risk 




the clear safety signal in favor of NOACs over warfarin was evident irrespective of age strata, 
being most marked in the most elderly.   
 





The incidence and prevalence of atrial fibrillation (AF) significantly increase with age,1 
and stroke prevention is the cornerstone for the management of elderly AF patients given 
their high risk of ischemic stroke.2 Age is a powerful driver of stroke risk but 
thromboprophylaxis in the elderly is challenging, requiring a balance between 
thromboembolism prevention and serious bleeding.3     
Prescription rates of OACs are generally suboptimal among the elderly, for example, 
being only 36% for patients aged >85 years in a general practice cohort from the United 
Kingdom.4 In our recent report, only 3.9% of newly-diagnosed Asian AF patients aged >90 
years were treated with warfarin in the Taiwan nationwide cohort.5 Several reasons could 
partly explain the underuse of OACs among the elderly, such as the relative lacking of 
evidence, the physician’s concern of bleeding and an in bility of some patients to cope with 
warfarin monitoring. 
The introduction of the non-vitamin K antagonist OACs (NOACs) have provided an 
equally effective, safer and more convenient choice than warfarin,6 NOACs may overcome 
some of the reasons of the underuse of warfarin in the elderly. Although no randomized trial 
has specifically randomized elderly adults to compare NOACs with warfarin, sub-analyses of 
four landmark NOACs trials (RELY, ROCEKT-AF, ARISTOTLE, and ENGAGE AF-TIMI 
48) in different age strata have been published.7-10 The results of these studies have shown 
that the benefits of NOACs versus warfarin were consistent in patients with AF regardless of 
age. In these studies, “the elderly” were defined as p tients aged > 75 years, and data about 
the comparisons of NOACs and warfarin in even older patients (e.g. age > 90 years) were 




In this nationwide cohort study, we aimed to compare the risks of ischemic stroke, intra-
cranial hemorrhage (ICH), major bleeding and mortality mong AF patients aged > 65 years 
treated with NOACs and warfarin. Second, these patients were stratified into different age 
strata (age 65-74, 75-89 and >90 years). We hypothesized that the benefits of NOACs were 





This study used the “National Health Insurance Research Database (NHIRD)” provided 
by Health and Welfare Data Science Center (HWDC), Ministry of Health and Welfare 
(MOHW), Taiwan. The National Health Insurance (NHI) system is a mandatory universal 
health insurance program that offers comprehensive medical care coverage to all Taiwanese 
residents. NHIRD consists of detailed health care data from >23 million enrollees, 
representing >99% of Taiwan’s population. In this cohort dataset, the patients’ original 
identification numbers have been encrypted to protect heir privacy, but the encrypting 
procedure was consistent, so that a linkage of the claims belonging to the same patient was 
feasible within the NHI database and can be followed continuously. The descriptions about 
Taiwan NHIRD have been reported in our previous studies.11-16  
Study cohort and study design 
From January 1, 2012 to December 31, 2015, a total of 324,825 AF patients aged ≥ 20 
were identified. AF was diagnosed using the Internatio l Classification of Diseases (ICD), 
Ninth Revision, Clinical Modification (ICD-9-CM) codes (427.31). To ensure the accuracy 
of diagnosis, we defined patients with AF only when it was a discharge diagnosis or 
confirmed for at least 2 times in the outpatient department. The diagnostic accuracy of AF 
using this definition in NHIRD has been validated previously.17 Among the study population, 
there were 64,169 AF patients aged > 65 years who received at least 1 NOAC (dabigatran, 
rivaroxaban, or apixaban) or warfarin prescription. The mean drug adherence rate of OACs, 
calculated based on proportion of days covered withOACs during the entire follow-up period 
for each patient, was 69%. The risks of ischemic stroke, ICH, major bleeding and mortality 




different age strata; that is 65-74 years, 75-89 years and >90 years. The flowchart of study 
design is shown in Figure 1.  
Calculation of scores and clinical outcomes 
The CHA2DS2-VASc score was calculated for each patient by assigning 1 point each for 
age between 65 and 74 years, history of hypertension, diabetes, congestive heart failure, 
vascular disease (myocardial infarction or peripheral a tery disease), and female gender, and 
2 points each for a history of a stroke, transient ischemic attack (TIA), or age ≥ 75 years.18 
The HAS-BLED score was calculated by assigning 1 point each for hypertension, abnormal 
renal or liver function, stroke, bleeding history, age 65 years or older, and antiplatelet drug or 
alcohol use.19 Since the information of international normalized ratio (INR) of warfarin was 
not available in the Taiwan registry database, the component of “labile INR,” was excluded 
from the HAS-BLED score in the present study, consistent with prior registry studies. Also, 
abnormal renal and liver function were defined by the ICD-9-CM codes rather than 
laboratory data. 
We analyzed the risks of several clinical events, including ischemic stroke, ICH, major 
bleeding, all-cause mortality and composite adverse vents (ischemic stroke or ICH or major 
bleeding or all-cause mortality). Ischemic stroke was diagnosed using ICD-9-CM codes, with 
concomitant imaging studies of the brain, including computed tomography or magnetic 
resonance imaging. The accuracy of diagnosis of ischemic stroke in Taiwan’s NHIRD has 
been reported to be around 94%.20 Another validation study also demonstrated that the 
diagnostic accuracy of ischemic stroke in NHIRD was high, with the positive predictive 
value and sensitivity of 88.4% and 97.3%, respectivly.21 The safety endpoint was the 




defined as ICH or bleeding from gastrointestinal or genitourinary or respiratory tract 
requiring hospitalization. 
Propensity match analysis 
We performed propensity score–matched analyses of NOACs versus warfarin among 
whole study population and patients at each age strata. We calculated propensity scores for 
the likelihoods of receiving NOACs compared to warfarin by multivariate logistic regression 
analyses, conditional on all baseline covariates listed in Table 1. The results of the propensity 
score models about the probabilities of the use of NOACs are shown in Supplemental Table 1, 
Supplemental Table 2, Supplemental Table 3 and Supplemental Table 4. After that, we 
matched patients in the warfarin group to those in the NOACs group with a 1:1 ratio on the 
basis of the closest propensity score for the use of NOACs within a threshold of ±0.01 using 
the greedy algorithm.  
Statistical analysis 
Data are presented as the mean value (standard deviation [SD]) for continuous variables 
and proportions for categorical variables. The differences between normally distributed 
continuous values were assessed using an unpaired 2-tailed t test. The differences between 
nominal variables were compared by Chi-square test. The incidences of ischemic stroke, ICH, 
major bleeding, all-cause mortality and composite adverse events were calculated from 
dividing the number of event by person-time at risk. The risk of adverse events was assessed 
using the Cox regression analysis. The proportional hazards assumption was tested using 
Schoenfeld residual test which showed no non-proportionality. The cumulative incidence 
curves of adverse events for patients receiving NOACs or warfarin in different age strata 




rank test. Absolute risk differences of ICH and comp site adverse events with NOACs versus 
warfarin in different age strata were calculated according to the crude event rates. The All 
statistical significances were set at a p < 0.05. 
The present study was approved by the Institutional Review Board (IRB) at Taipei 
Veterans General Hospital (2016-03-002AC and 2019-10-002AC), Taipei, Taiwan and the 






Clinical characteristics of the study population are shown in Table 1. Patients on 
NOACs tended to be older and male, with more prevalent hypertension, prior stroke/TIA and 
hyperlipidemia, with less prevalent heart failure, vascular disease, abnormal renal function, 
anemia and concomitant antiplatelet drugs. Mean CHA2DS2-VASc score was lower and  
HAS-BLED score higher in warfarin users compared to NOAC users (Table 1).  Similar 
trends were seen in clinical characteristics of study patients taking NOAC or warfarin, 
stratified by different age categories, as shown in Table 2.     
Propensity score models for the use of NOACs are shown in Supplemental Tables 1-4. 
Increased probabilities of the use of NOACs amongst all patients were evident for increasing 
age, males, hypertension, diabetes, stroke/TIA, hyperlipidemia, abnormal liver function and 
history of bleeding; with less NOAC use for heart failure, vascular disease, abnormal renal 
function, anemia and concomitant use of antiplatelet drugs. Broadly similar trends were seen 
when stratified by different age categories. 
Crude event rates (%/year) of patients in different age strata are shown in Figure 2. As 
expected, ischemic stroke, ICH, major bleeding, mortality and adverse events increased with 
increasing age. The relative risk of events of patients treated with NOACs compared to 
warfarin are shown in Figure 3. Overall NOACs were associated with significantly lower 
risks of ischemic stroke (adjusted hazard ratio [aHR] 0.869, 95%CI 0.812-0.931), ICH (aHR 
0.524, 95%CI 0.456-0.601), major bleeding (aHR 0.824, 95%CI 0.776-0.875), mortality 
(aHR 0.511, 95%CI 0.491-0.532) and adverse events (aHR 0.646, 95%CI 0.625-0.667) after 
the adjustments for variables with a p value < 0.05 between 2 groups in Table 1.  
For ischemic stroke, there was heterogeneity in treatm nt effect for NOACs vs 




interaction [pint], <0.001). For ICH and composite adverse events, NOACs were significantly 
better compared to warfarin, especially in the very lderly for ICH (pint <0.001).  For major 
bleeding, there was also significant heterogeneity, particularly in the very elderly (age ≥90) 
subgroup, where there was no statistical difference for NOACs compared to warfarin (pint 
<0.001).    
The cumulative incidence curves of clinical events by age strata are shown in Figure 4. 
As expected, older patients were at higher risks of i chemic stroke, ICH, major bleeding and 
mortality, with generally better benefits with NOACs versus warfarin. Importantly, the risk of 
ICH was even lower for the very elderly patients trea ed with NOACs compared to younger 
patients treated with warfarin.  
Figure 5A shows the annual event rates of ICH of patients treated with warfarin and 
NOACs from the young to old age strata at an interval of 5 years, and the absolute risk 
difference of ICH between warfarin and NOACs was even more evident in the elderly. ICH 
absolute event reductions (per 1000 patient-years) with NOACs compared to warfarin was 
even larger among the elderly (Figure 5B). Similar p tterns were also noted for overall 
adverse events (Figure 6A and Figure 6B). 
 
Propensity matched analysis 
Clinical characteristics of the whole cohort and by age strata following propensity score 
matching are provided in Supplemental Table 5 and Supplemental Table 6, respectively. 
Baseline characteristics and propensity scores were not significantly different between 
patients treated with warfarin or NOACs after the matching. Consistent with the overall main 
analysis, NOACs were associated with significantly lower ischemic stroke, ICH, major 
bleeding, mortality and adverse events in the propensity matched analysis (Supplemental 









In this paper, our principal findings are as follows: (i) NOACs were associated with a 
significantly lower risk of ischemic stroke, ICH, major bleeding, mortality and overall 
adverse events compared to warfarin among AF patients aged > 65 years; (ii) there was 
heterogeneity in treatment effect for NOACs versus warfarin in different age strata, but the 
results still favored NOACs even among the very elderly (> 90 years); and (iii) compared to 
warfarin, the absolute risk differences and reduction of event numbers for ICH and composite 
adverse events with NOAC users were even greater among the elderly. 
The NOACs have changed the landscape for stroke prevention in AF,2,22 although 
regional differences in prescribing are evident.23 Nevertheless, NOACs are the preferred 
OAC option in guidelines.3,24,25 In Taiwan, every NOAC was fully reimbursed by Taiwn 
NHI program, mainly following the inclusion criteria of RE-LY trial, and could be prescribed 
as the first-line therapy for stroke prevention without trying warfarin first. Even though, 
OACs were only prescribed in 25.8% of patients aged > 65 years in the present study, which 
was much lower than that reported from GARFIELD-AF (71.1%) and GLORIA-AF (60.7%) 
registries.26,27 More efforts are necessary to improve the prescription rate of OACs in the 
daily practice in Taiwan.  
In the published sub-analysis of PREFER in AF (PREvention oF thromboembolic 
events-European Registry in Atrial Fibrillation), the annual risks of thromboembolism and 
major bleeding for anticoagulated European AF patients aged > 85 years were 4.3% and 
4.0%, respectively,28 which were numerically lower than that of Taiwan AF patients aged 75-
89 years with a mean age of 81 years in the present study. These data were consistent to that 
of the previous report demonstrating that Asian AF patients were associated a higher risk of 
ischemic stroke and bleeding compared to non-Asians in several pivotal randomized trials 




The use of NOACs are supported by large randomized controlled trials (RCTs) showing 
clear benefits for NOACs vs warfarin, for efficacy and safety.6 These RCT data are 
supplemented by ‘real world’ post-marketing observational data confirming the effectiveness 
and safety for NOACs compared to warfarin,30,31 even in large cohorts from the Far East.32,33  
The present ‘real-world’ analysis from a nationwide cohort extends these observations in a 
large nationwide cohort from Asia, particularly showing the safety of NOACs in the very 
elderly patients.  In addition, when compared to warfarin, a clear NOAC benefit for ischemic 
stroke was evident at age ≥75, while the benefit in relation to ICH, mortality and adverse 
events was even evident from age ≥65.  Given that even the historical randomized trials show 
a benefit for OAC in reducing stroke (by 64%) and all-c use mortality (by 26%) compared to 
control or placebo.34 A lower risk of mortality observed in patients treat d with NOACs 
compared to warfarin even in younger age strata (age 65-74 years) is relevant, 
notwithstanding the possibility that some deaths in observational cohorts may be fatal strokes 
since not all outcomes are adjudicated and postmorte s are not mandated.   
The safety is a major concern for the prescriptions f OACs for the elderly AF 
population in the daily practice. In the present study, the safety signal in favor of NOACs 
over warfarin was evident irrespective of age strata, being most marked in the very elderly 
(age > 90 years) for the risk of ICH. Indeed, the absolute risk difference and reduction of 
event numbers in ICH and composite adverse events between patients treated with warfarin 
and NOACs were greatest for the older population. It means that the older the patients, the 
more benefits the NOACs could provide compared to warfarin. Our findings were similar to 
that reported from PREFER in AF showing that the absolute benefit of OAC is highest in 
very elderly patients.28 In addition to the comparisons between warfarin and NOACs, the 
annual risk of ischemic stroke, ICH and major bleeding we reported here is also useful for 





There are several limitations of the present study. First, information about international 
normalized ratio and the time in therapeutic range (TTR) for warfarin was lacking in this 
nationwide registry. In the RE-LY trial, the TTR for warfarin was only 44% in Taiwan.35 
Since a higher TTR is associated with a lower risk of ischemic stroke and ICH for AF 
patients receiving warfarin, the benefits of NOACs compared to warfarin may be attenuated 
if the TTR of warfarin could be higher. Second, the present study only enrolled Asian 
patients, and whether the results can be extrapolated to other populations whose the risk of 
stroke and ICH may be different remains uncertain. Third, patients with persistent AF had a 
higher risk of thromboembolic events and worse survival compared with paroxysmal AF in 
the subanalysis of ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in 
Atrial Fibrillation) trial.36 Since data about the subtypes of AF were not available from this 
nationwide dataset, we were not able to know whether types of AF would have impacts on 
our analysis. Fourth, the data we presented here webased on retrospective analyses of a 
nationwide cohort, and therefore, some unmeasured confounders and biases (e.g., 
confounding by indication) may still be present even we have tried to adjust for the 
differences between patients treated with warfarin nd NOACs using the multivariate Cox 
regression and propensity matching analyses. Owing to this important limitation, we can only 
report an “association” between the use of NAOCs and the lower risks of clinical events 
compared to warfarin rather than “causation”, and a further prospective and randomized 
study is necessary to confirm our findings. Lastly, we considered different NOACs as a 
single group and did not perform separate analysis for each NOAC since these analyses may 
be even confounded by incidations and doctors’ decisions for choosing a particular NOAC. 




we were not able to further classify it as appropriate or inappropriate dose since data about 
body weigth and renal function necessary for the classification were not recorded in our 
database.   
 
Conclusion  
Compared to warfarin, NOACs were associated with a significantly lower risk of 
adverse events, with heterogeneity in treatment effects among different age strata. Overall, 
the clear safety signal in favor of NOACs over warfarin was evident irrespective of age strata, 
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Age, mean (SD) 78.54 (7.67) 78.65 (7.44) 78.26 (7.86) < 0.001 
Age ≥ 75 years, n (%) 43568 (67.9) 31462 (68.9) 12106 (65.3) < 0.001 
Age 65-74 years, n (%) 20601 (32.1) 14170 (31.1) 6431 (34.7) < 0.001 
Sex (male), n (%) 34042 (53.1) 24651 (54.0) 9391 (50.7) < 0.001 
Comorbidities, n (%)     
    Hypertension 58275 (90.8) 41638 (91.2) 16637 (89.8) < 0.001 
    Diabetes mellitus 28925 (45.1) 20517 (45.0) 8408 (45.4) 0.361 
    Heart failure 36430 (56.8) 24996 (54.8) 11434 (61.7) < 0.001 
Prior stroke/TIA 30383 (47.3) 22452 (49.2) 7931 (42.8) < 0.001 
Vascular disease 10348 (16.1) 6973 (15.3) 3375 (18.2) < 0.001 
COPD 29116 (45.4) 20601 (45.1) 8515 (45.9) 0.069 
Hyperlipidemia 37152 (57.9) 26895 (58.9) 10257 (55.3) < 0.001 
Autoimmune diseases 7238 (11.3) 5127 (11.2) 2111 (1.4) 0.580 
Cancer 11114 (17.3) 7861 (17.2) 3253 (17.5) 0.330 
Abnormal renal function 15059 (23.5) 9505 (20.8) 5554 (30.0) < 0.001 
Abnormal liver function 22274 (34.7) 15914 (34.9) 6360 (34.3) 0.173 
Anemia 13605 (21.2) 8736 (19.1) 4869 (26.3) < 0.001 
History of bleeding  27661 (43.1) 19672 (43.1) 7989 (43.1) 0.977 
Alcohol excess/abuse, n (%) 560 (0.9) 408 (0.9) 152 (0.8) 0.351 
Use of anti-platelet drugs, n (%) 8032 (12.5) 4511 (9.9) 3521 (19.0) < 0.001 
Use of NSAIDs, n (%) 2780 (4.3) 1968 (4.3) 812 (4.4) 0.703 
CHA2DS2-VASc score, mean (SD) 5.18 (1.67) 5.20 (1.64) 5.15 (1.73) 0.003 
HAS-BLED-score, mean (SD) 3.54 (1.23) 3.52 (1.19) 3.59 (1.30) < 0.001 
COPD = chronic obstructive pulmonary disease; NOACs = non-vitamin K antagonist oral 
anticoagulants; NSAIDs = non-steroidal anti-inflammatory drugs; SD = standard deviation; 





Table 2. Clinical characteristics of study patients stratified in different age categories 
Variables 
















Age, mean (SD) 69.92 (2.88) 69.61 (2.98) < 0.001  81.44 (4.11) 81.50 (4.14) 0.200  92.35 (2.46) 92.51 (2.63) 0.430 
Age ≥ 75 years, n (%) - - -  28179 (100) 10609 (100) -  3283 (100) 1497 (100) - 
Age 65-74 years, n (%) 14170 (100) 6431 (100) -  - - -  - - - 
Sex (male), n (%) 8691 (61.3) 3690 (57.4) < 0.001  14375 (51.0) 5055 (47.5) < 0.001  1585 (48.3) 646 (43.2) 0.001 
Comorbidities, n (%)            
    Hypertension 12554 (88.6) 5384 (83.7) < 0.001  26004 (92.3) 9833 (92.7) 0.181  3080 (93.8) 1420 (94.9) 0.156 
    Diabetes mellitus 6601 (46.6) 2863 (44.5) 0.006  12655 (44.9) 4944 (46.6) 0.003  1261 (38.4) 601 (40.1) 0.253 
    Heart failure 6489 (45.8) 3436 (53.4) < 0.001  16248 (57.7) 6882 (64.9) < 0.001  2259 (68.8) 1116 (74.5) < 0.001 
Prior stroke/TIA 6228 (44.0) 2164 (33.6) < 0.001  14389 (51.1) 5005 (47.2) < 0.001  1835 (55.9) 762 (50.9) 0.001 
Vascular disease 1872 (13.2) 964 (15.0) 0.001  4528 (16.1) 2061 (19.4) < 0.001  573 (17.5) 350 (23.4) < 0.001 
COPD 4897 (34.6) 2281 (35.5) 0.204  13765 (48.8) 5362 (50.5) 0.003  1939 (59.1) 872 (58.2) 0.597 
Hyperlipidemia 9051 (63.9) 3800 (59.1) < 0.001  16311 (57.9) 5822 (54.9) < 0.001  1533 (46.7) 635 (42.4) 0.006 
Autoimmune diseases 1407 (9.9) 642 (10.0) 0.906  3374 (12.0) 1294 (12.2) 0.548  346 (10.5) 175 (11.7) 0.236 
Cancer 1871 (13.2) 909 (14.1) 0.070  5267 (18.7) 2038 (19.2) 0.244  723 (22.0) 306 (20.4) 0.217 
Abnormal renal function 2489 (17.6) 1737 (27.0) < 0.001  6286 (22.3) 3344 (31.5) < 0.001  730 (22.2) 473 (31.6) < 0.001 
Abnormal liver function 5330 (37.6) 2368 (36.8) 0.276  9657 (34.3) 3579 (33.7) 0.322  927 (28.2) 413 (27.6) 0.643 
Anemia 1757 (12.4) 1298 (20.2) < 0.001  6044 (21.4) 3046 (28.7) < 0.001  935 (28.5) 525 (35.1) < 0.001 
History of bleeding  5493 (38.8) 2517 (39.1) 0.611  12634 (44.8) 4803 (45.3) 0.440  1545 (47.1) 669 (44.7) 0.127 
Alcohol excess/abuse, n (%) 247 (1.7) 96 (1.5) 0.193  197 (0.7) 54 (0.5) 0.558  4 (0.1) 2 (0.1) 0.917 




Use of NSAIDs, n (%) 565 (4.0) 293 (4.6) 0.058  1302 (4.6) 455 (4.3) 0.161  101 (3.1) 64 (4.3) 0.035 
CHA2DS2-VASc score, mean (SD) 4.21 (1.49) 4.07 (1.55) < 0.001  5.62 (1.51) 5.70 (1.53) < 0.001  5.82 (1.45) 5.92 (1.49) 0.038 
HAS-BLED-score, mean (SD) 3.35 (1.22) 3.34 (1.37) 0.502  3.59 (1.18) 3.73 (1.25) < 0.001  3.60 (1.14) 3.70 (1.19) 0.004 
COPD = chronic obstructive pulmonary disease; NOACs = non-vitamin K antagonist oral anticoagulants; NSAIDs = non-steroidal anti-





Figure 1 A flowchart of the enrollment of the study cohort. From January 1, 2012 to 
December 31, 2015, a total of 64,169 AF patients aged ≥ 65 years who have received at least 
1 NOAC (dabigatran, rivaroxaban, or apixaban) or wafarin prescription constituted the study 
cohort. The risks of ischemic stroke, ICH, major bleeding and mortality were compared 
between NOACs and warfarin in all patients and those in each age groups; that is 65-74 years, 
75-89 years and >90 years.  
A = apixaban; AF = atrial fibrillation; D = dabigatr n; ICH = intra-cranial hemorrhage; 
NHIRD = National Health Insurance Research Database; NOACs = non-vitamin K 
antagonist oral anticoagulants; OACs = oral anticoagulants; R = rivaroxaban 
 
Figure 2 Event rate (%/year) in different age strata. The risk of ischemic stroke, ICH, 
major bleeding, mortality and adverse events increased with increasing age.   
CI = confidence interval; ICH = intra-cranial hemorrhage 
 
Figure 3 Risk of events of patients treated with NOACs compared to warfarin. NOACs 
were associated with a significantly lower risk of ischemic stroke, ICH, major bleeding, 
mortality and adverse events compared to warfarin, w th heterogeneity in treatment effects 
among different age strata. Overall, the clear safety signal in favor of NOACs over warfarin 
was evident irrespective of age strata, being most arked in the elderly. 
*HRs were adjusted for the variables whose p values w re < 0.05 between warfarin and 
NOAC groups listed in Table 1 for overall comparison  and Table 2 for comparisons in 
different age strata. 
CI = confidence interval; ICH = intra-cranial hemorrhage; HR = hazard ratio; NOACs = non-





Figure 4 Cumulative incidence curves of clinical events. Older patients were at higher 
risks of ischemic stroke, ICH, major bleeding and mortality, with generally better benefits 
with NOACs versus warfarin. Most importantly, the risk of ICH was even lower for the very 
elderly patients treated with NOACs compared to younger patients treated with warfarin. 
ICH = intra-cranial hemorrhage; NOACs = non-vitamin K antagonist oral anticoagulants 
 
Figure 5 Annual risk of ICH (A) and event reduction with NOACs compared to 
warfarin (B).  The absolute risk difference of ICH between warfarin and NOACs was even 
more evident in the elderly (Figure 5A). Also, the ICH event reduction (per 1000 patient-
years) with NOACs compared to warfarin was even larger among the elderly (Figure 5B).  
CI = confidence interval; ICH = intra-cranial hemorrhage; NOACs = non-vitamin K 
antagonist oral anticoagulants 
 
Figure 6 Annual risk of adverse events (A) and event reduction with NOACs compared 
to warfarin (B).  The absolute risk difference (Figure 6A) and risk eduction (per 100 patient-
years) of composite adverse events with NOACs compared to warfarin (Figure 6B) were 
even larger among the elderly.  
CI = confidence interval; NOACs = non-vitamin K antgonist oral anticoagulants 
 




Figure 4 
 
 

